The microbiota in inflammatory bowel disease with resistance to anti-TNF therapy.

炎症性肠病中的微生物群对抗 TNF 疗法具有抵抗力。

• 批准号: 23590948
• 负责人: OKAZAWA Akira
• 金额: $ 3.33万
• 依托单位: Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23590948/
• 关键词: 腸内細菌; 炎症性腸疾患; probiotics; 腸内細菌フローラ

In this study, we analyzed the bacterial composition of fecal samples from inflammatory bowel disease (IBD). We found that the prevalence of one of Clostridia was lower in active ulcerative colitis (UC) than quiescent UC. We stimulated colitic lamina propria mononuclear cells (LPMC) from UC patients and IBD model mice with heat-killed this Clostridia. LPMC incubated with Clostridia produced higher amounts of IL-10 compared to controls. The results suggest Clostridia can suppress intestinal inflammation, probably through IL-10 induction. Therefore FS can be a new strategy of IBD therapy.

在这项研究中，我们分析了炎症性肠病（IBD）粪便样本的细菌组成。我们发现，梭菌的患病率之一，活动期溃疡性结肠炎（UC）比静止期UC。我们用热灭活的梭菌刺激UC患者和IBD模型小鼠的结肠炎固有层单核细胞（LPMC）。与对照相比，与梭菌孵育的LPMC产生更高量的IL-10。结果表明，梭菌可以抑制肠道炎症，可能通过IL-10诱导。因此，FS可作为IBD治疗的一种新策略。